Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XmAb20717 in Advanced Biliary Tract Cancers
NCT05297903Phase 2Completed
- Sponsor
- Abramson Cancer Center
- Start
- Apr 2022
- Primary completion
- Jul 2026
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of vudalimab in biliary tract cancer (BTC), sponsored by Abramson Cancer Center. Started Apr 2022; status: completed.
02
Drugs
vudalimab
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT05297903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05297903.